{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:10:04Z","timestamp":1793733004184,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["721236"],"award-info":[{"award-number":["721236"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["PEJ-2018-TL\/BMD-11080"],"award-info":[{"award-number":["PEJ-2018-TL\/BMD-11080"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12325-020-01566-w","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T09:03:27Z","timestamp":1607159007000},"page":"1035-1054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-0466","authenticated-orcid":false,"given":"Dora","family":"Koller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Almenara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Navares-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Santos-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pintos-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"1566_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114:169\u201379.","journal-title":"Br Med Bull"},{"issue":"Suppl 10","key":"1566_CR2","first-page":"37","volume":"58","author":"NA Moore","year":"1997","unstructured":"Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry. 1997;58(Suppl 10):37\u201344.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"1566_CR3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","volume":"32","author":"E Stip","year":"2010","unstructured":"Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32(Suppl 1):S3-20.","journal-title":"Clin Ther"},{"key":"1566_CR4","unstructured":"Food and Drug Administration. ABILIFY (aripiprazole) label. Otsuka Pharmaceutical. http:\/\/www.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021436s038,021713s030,021729s022,021866s023lbl.pdf. Accessed 1 Jul 2014."},{"key":"1566_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177\u201393.","journal-title":"Clin Pharmacokinet"},{"key":"1566_CR6","first-page":"502697","volume":"2013","author":"SI Bargiota","year":"2013","unstructured":"Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The effects of antipsychotics on prolactin levels and women\u2019s menstruation. Schizophr Res Treat. 2013;2013:502697.","journal-title":"Schizophr Res Treat"},{"key":"1566_CR7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","volume":"166","author":"DE Casey","year":"2003","unstructured":"Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology. 2003;166:391\u20139.","journal-title":"Psychopharmacology"},{"key":"1566_CR8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1530\/acta.0.1040266","volume":"104","author":"TR Hall","year":"1983","unstructured":"Hall TR, Harvey S, Chadwick A. Mechanism of serotonin effects on prolactin and growth hormone secretion in domestic fowl. Acta Endocrinol (Copenh). 1983;104:266\u201371.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1566_CR9","first-page":"2635","volume":"11","author":"G Di Sciascio","year":"2015","unstructured":"Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635\u201347.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1566_CR10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","volume":"31","author":"R L\u00f3pez-Rodr\u00edguez","year":"2011","unstructured":"L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Novalbos J, Pelegrina ML, Ochoa D, Abad-Santos F. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol. 2011a;31:555\u201362.","journal-title":"J Clin Psychopharmacol"},{"key":"1566_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2016.06.002","volume":"72","author":"I Miura","year":"2016","unstructured":"Miura I, Zhang J-P, Hagi K, et al. Variants in the DRD2 locus and antipsychotic-related prolactin levels: a meta-analysis. Psychoneuroendocrinology. 2016;72:1\u201310.","journal-title":"Psychoneuroendocrinology"},{"key":"1566_CR12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1819.2012.02391.x","volume":"66","author":"G Nagai","year":"2012","unstructured":"Nagai G, Mihara K, Nakamura A, et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia: prolactin response to aripiprazole. Psychiatry Clin Neurosci. 2012;66:518\u201324.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1566_CR13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/bcpt.13323","volume":"126","author":"D Koller","year":"2020","unstructured":"Koller D, Belmonte C, Saiz-Rodr\u00edguez M, et al. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers. Basic Clin Pharmacol Toxicol. 2020;126:236\u201346.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1566_CR14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009;70:572\u201381.","journal-title":"J Clin Psychiatry"},{"key":"1566_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123:225\u201333.","journal-title":"Schizophr Res"},{"key":"1566_CR16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12888-017-1539-0","volume":"17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Liu Y, Su Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17:373.","journal-title":"BMC Psychiatry"},{"key":"1566_CR17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.psyneuen.2017.12.004","volume":"88","author":"LK Townsend","year":"2018","unstructured":"Townsend LK, Peppler WT, Bush ND, Wright DC. Obesity exacerbates the acute metabolic side effects of olanzapine. Psychoneuroendocrinology. 2018;88:121\u20138.","journal-title":"Psychoneuroendocrinology"},{"key":"1566_CR18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4055\/cios.2014.6.1.103","volume":"6","author":"J Kim","year":"2014","unstructured":"Kim J, Shin W. How to do random allocation (randomization). Clin Orthop Surg. 2014;6:103\u20139.","journal-title":"Clin Orthop Surg"},{"key":"1566_CR19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.talanta.2019.01.112","volume":"198","author":"D Koller","year":"2019","unstructured":"Koller D, Zubiaur P, Saiz-Rodr\u00edguez M, Abad-Santos F, Wojnicz A. Simultaneous determination of six antipsychotics, two of their metabolites and caffeine in human plasma by LC-MS\/MS using a phospholipid-removal microelution-solid phase extraction method for sample preparation. Talanta. 2019;198:159\u201368.","journal-title":"Talanta"},{"key":"1566_CR20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/bcp.14300","volume":"86","author":"D Koller","year":"2020","unstructured":"Koller D, Saiz-Rodr\u00edguez M, Zubiaur P, et al. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. Br J Clin Pharmacol. 2020;86:2051\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"1566_CR21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/tpj.2014.67","volume":"15","author":"M Apell\u00e1niz-Ruiz","year":"2015","unstructured":"Apell\u00e1niz-Ruiz M, Inglada-P\u00e9rez L, Naranjo MEG, et al. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J. 2015;15:288\u201392.","journal-title":"Pharmacogenomics J"},{"key":"1566_CR22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"1566_CR23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","volume":"19","author":"KE Caudle","year":"2017","unstructured":"Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19:215\u201323.","journal-title":"Genet Med"},{"key":"1566_CR24","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00228-017-2323-2","volume":"73","author":"AB Sanchez Spitman","year":"2017","unstructured":"Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol. 2017;73:1589\u201398.","journal-title":"Eur J Clin Pharmacol"},{"key":"1566_CR25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/0269881119827959","volume":"33","author":"M Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez M, Ochoa D, Belmonte C, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33:522\u201331.","journal-title":"J Psychopharmacol"},{"key":"1566_CR26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3892\/ol.2014.1857","volume":"7","author":"D Vivona","year":"2014","unstructured":"Vivona D, Lima LT, Rodrigues AC, et al. ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett. 2014;7:1313\u20139.","journal-title":"Oncol Lett"},{"key":"1566_CR27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1345\/aph.1R123","volume":"46","author":"TR Einarson","year":"2012","unstructured":"Einarson TR, Hemels ME, Nuamah I, Gopal S, Coppola D, Hough D. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Ann Pharmacother. 2012;46:1322\u201330.","journal-title":"Ann Pharmacother"},{"key":"1566_CR28","doi-asserted-by":"crossref","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","volume":"6","author":"VL Albaugh","year":"2011","unstructured":"Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One. 2011;6:e22662.","journal-title":"PLoS One"},{"key":"1566_CR29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22:46\u201355.","journal-title":"J Psychopharmacol"},{"key":"1566_CR30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yfrne.2017.02.003","volume":"45","author":"\u00c1L Montejo","year":"2017","unstructured":"Montejo \u00c1L, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25\u201334.","journal-title":"Front Neuroendocrinol"},{"key":"1566_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hup.2308","volume":"28","author":"T Cabaleiro","year":"2013","unstructured":"Cabaleiro T, L\u00f3pez-Rodr\u00edguez R, Ochoa D, Rom\u00e1n M, Novalbos J, Abad-Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol. 2013;28:205\u201314.","journal-title":"Hum Psychopharmacol"},{"key":"1566_CR32","first-page":"929","volume":"3","author":"DL Torre","year":"2007","unstructured":"Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007;3:929\u201351.","journal-title":"Ther Clin Risk Manag"},{"key":"1566_CR33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3928\/00485713-20150501-09","volume":"45","author":"BE Miyamoto","year":"2015","unstructured":"Miyamoto BE, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann. 2015;45:266\u201372.","journal-title":"Psychiatr Ann"},{"key":"1566_CR34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1530\/acta.0.0830711","volume":"83","author":"T Yamaji","year":"1976","unstructured":"Yamaji T, Shimamoto K, Ishibashi M, Kosaka K, Orimo H. Effect of age and sex on circulating and pituitary prolactin levels in human. Acta Endocrinol (Copenh). 1976;83:711\u20139.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"1566_CR35","doi-asserted-by":"publisher","unstructured":"Yoshida K, M\u00fcller DJ. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol Neuropsychiatry. 2018;5(Suppl 1):1\u201326. https:\/\/doi.org\/10.1159\/000492332.","DOI":"10.1159\/000492332"},{"key":"1566_CR36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12888-018-1817-5","volume":"18","author":"S Hattori","year":"2018","unstructured":"Hattori S, Suda A, Kishida I, et al. Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia. BMC Psychiatry. 2018;18:231.","journal-title":"BMC Psychiatry"},{"key":"1566_CR37","first-page":"51","volume":"42","author":"RR Conley","year":"2005","unstructured":"Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci. 2005;42:51\u201360.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"1566_CR38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","volume":"187","author":"RS Kern","year":"2006","unstructured":"Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology. 2006;187:312\u201320.","journal-title":"Psychopharmacology"},{"key":"1566_CR39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","volume":"31","author":"R L\u00f3pez-Rodr\u00edguez","year":"2011","unstructured":"L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Novalbos J, Pelegrina ML, Ochoa D, Abad-Santos F. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol. 2011b;31:555\u201362.","journal-title":"J Clin Psychopharmacol"},{"key":"1566_CR40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","volume":"186","author":"R-R Wu","year":"2006","unstructured":"Wu R-R, Zhao J-P, Liu Z-N, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 2006;186:572\u20138.","journal-title":"Psychopharmacology"},{"key":"1566_CR41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2337\/diab.33.5.486","volume":"33","author":"KS Polonsky","year":"1984","unstructured":"Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Diabetes. 1984;33:486\u201394.","journal-title":"Diabetes"},{"key":"1566_CR42","first-page":"198","volume":"34","author":"SM Najjar","year":"2019","unstructured":"Najjar SM, Perdomo G. Hepatic insulin clearance: mechanism and physiology. Physiology (Bethesda). 2019;34:198\u2013215.","journal-title":"Physiology (Bethesda)"},{"key":"1566_CR43","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","volume":"62","author":"KL Teff","year":"2013","unstructured":"Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen H-L, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62:3232\u201340.","journal-title":"Diabetes"},{"key":"1566_CR44","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.sjbs.2018.05.027","volume":"25","author":"HA Khan","year":"2018","unstructured":"Khan HA, Sobki SH, Ekhzaimy A, Khan I, Almusawi MA. Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals. Saudi J Biol Sci. 2018;25:1729\u201332.","journal-title":"Saudi J Biol Sci"},{"key":"1566_CR45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.biocel.2007.10.016","volume":"40","author":"GSD Marco","year":"2008","unstructured":"Marco GSD, Colucci JA, Fernandes FB, Vio CP, Schor N, Casarini DE. Diabetes induces changes of catecholamines in primary mesangial cells. Int J Biochem Cell Biol. 2008;40:747\u201354.","journal-title":"Int J Biochem Cell Biol"},{"key":"1566_CR46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13098-017-0295-0","volume":"9","author":"T Bozek","year":"2017","unstructured":"Bozek T, Blazekovic A, Perkovic MN, et al. The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:97.","journal-title":"Diabetol Metab Syndr"},{"key":"1566_CR47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1345\/aph.19327","volume":"34","author":"TL Bettinger","year":"2000","unstructured":"Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother. 2000;34:865\u20137.","journal-title":"Ann Pharmacother"},{"key":"1566_CR48","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/sj.npp.1301392","volume":"32","author":"DW Haupt","year":"2007","unstructured":"Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007;32:2561\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"1566_CR49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.403","volume":"17","author":"K Linnet","year":"2002","unstructured":"Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol Clin Exp. 2002;17:233\u20138.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1566_CR50","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bdi.12294","volume":"17","author":"S Bonaccorso","year":"2015","unstructured":"Bonaccorso S, Sodhi M, Li J, et al. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disord. 2015;17:528\u201335.","journal-title":"Bipolar Disord"},{"key":"1566_CR51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1359786806066040","volume":"20","author":"GP Reynolds","year":"2006","unstructured":"Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain\u2014mechanisms and genetics. J Psychopharmacol. 2006;20:15\u20138.","journal-title":"J Psychopharmacol"},{"key":"1566_CR52","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231\u201341.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1566_CR53","first-page":"83","volume":"4","author":"TJ Wallace","year":"2011","unstructured":"Wallace TJ, Zai CC, Brandl EJ, M\u00fcller DJ. Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmacogenomics Pers Med. 2011;4:83\u201393.","journal-title":"Pharmacogenomics Pers Med"},{"key":"1566_CR54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/13651501.2014.957705","volume":"18","author":"X Ma","year":"2014","unstructured":"Ma X, Maimaitirexiati T, Zhang R, et al. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. Int J Psychiatry Clin Pract. 2014;18:229\u201342.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1566_CR55","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1176\/ajp.2006.163.10.1821","volume":"163","author":"M Olfson","year":"2006","unstructured":"Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L\u2019Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163:1821\u20135.","journal-title":"Am J Psychiatry"},{"key":"1566_CR56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1365-2125.2003.01969.x","volume":"57","author":"L Purkins","year":"2003","unstructured":"Purkins L, Love ER, Eve MD, et al. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a phase I unit: effect of diet upon liver function tests and serum lipids. Br J Clin Pharmacol. 2003;57:199\u2013208.","journal-title":"Br J Clin Pharmacol"},{"key":"1566_CR57","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.tpj.6500474","volume":"8","author":"RC Smith","year":"2008","unstructured":"Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J. 2008;8:228\u201336.","journal-title":"Pharmacogenomics J"},{"key":"1566_CR58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","volume":"22","author":"AB Kohan","year":"2015","unstructured":"Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015;22:119\u201325.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1566_CR59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5483\/BMBRep.2005.38.2.238","volume":"38","author":"J-H Choi","year":"2005","unstructured":"Choi J-H, Zhang S-Y, Park K-W, et al. The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans. BMB Rep. 2005;38:238\u201342.","journal-title":"BMB Rep"},{"key":"1566_CR60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/WNF.0b013e31826818b6","volume":"35","author":"KFM Marwick","year":"2012","unstructured":"Marwick KFM, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. Clin Neuropharmacol. 2012;35:244\u201353.","journal-title":"Clin Neuropharmacol"},{"key":"1566_CR61","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1007\/s00213-014-3624-0","volume":"231","author":"M Gilca","year":"2014","unstructured":"Gilca M, Piriu G, Gaman L, et al. A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology. 2014;231:4703\u201310.","journal-title":"Psychopharmacology"},{"key":"1566_CR62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00004850-200101000-00007","volume":"16","author":"N Buchman","year":"2001","unstructured":"Buchman N, Strous RD, Ulman A-M, Lerner M, Kotler M. Olanzapine-induced leukopenia with human leukocyte antigen profiling. Int Clin Psychopharmacol. 2001;16:55\u20137.","journal-title":"Int Clin Psychopharmacol"},{"key":"1566_CR63","doi-asserted-by":"crossref","first-page":"e000013","DOI":"10.1136\/gpsych-2018-000013","volume":"31","author":"YK Malik","year":"2018","unstructured":"Malik YK, Sahoo S, Avasthi A. Olanzapine-induced leucopaenia and thrombocytopaenia in an elderly patient: a case report and review of the evidence. Gen Psychiatry. 2018;31:e000013.","journal-title":"Gen Psychiatry"},{"key":"1566_CR64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.yic.0000085241.99018.30","volume":"18","author":"S H\u00e4gg","year":"2003","unstructured":"H\u00e4gg S, T\u00e4tting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol. 2003;18:299\u2013300.","journal-title":"Int Clin Psychopharmacol"},{"key":"1566_CR65","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/15622970802032292","volume":"10","author":"D Mendhekar","year":"2009","unstructured":"Mendhekar D, Duggal H, Andrade C. Leukopenia and thrombocytopenia on adding aripiprazole to phenytoin. World J Biol Psychiatry. 2009;10:1043\u20134.","journal-title":"World J Biol Psychiatry"},{"key":"1566_CR66","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/bdi.12391","volume":"18","author":"CG Lambert","year":"2016","unstructured":"Lambert CG, Mazurie AJ, Lauve NR, et al. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord. 2016;18:247\u201360.","journal-title":"Bipolar Disord"},{"key":"1566_CR67","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1093\/schbul\/sby016.505","volume":"44","author":"T Iversen","year":"2018","unstructured":"Iversen T, Steen NE, Birkeland KI, et al. T229. Antipsychotic drug use and thyroid function in patients with severe mental disorders. Schizophr Bull. 2018;44:S205\u20136.","journal-title":"Schizophr Bull"},{"key":"1566_CR68","doi-asserted-by":"crossref","unstructured":"Lozano Ortiz R. Influence of drug treatment with antidepressants and antipsychotics on plasma urea levels. Neuropsychiatr Dis Treat. 2012;8:245\u20136.","DOI":"10.2147\/NDT.S32635"},{"key":"1566_CR69","doi-asserted-by":"crossref","first-page":"e019868","DOI":"10.1136\/bmjopen-2017-019868","volume":"8","author":"H-Y Wang","year":"2018","unstructured":"Wang H-Y, Huang CL-C, Feng IJ, Tsuang H-C. Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case-control study. BMJ Open. 2018;8:e019868.","journal-title":"BMJ Open"},{"key":"1566_CR70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-1781(98)00051-1","volume":"80","author":"JK Yao","year":"1998","unstructured":"Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80:29\u201339.","journal-title":"Psychiatry Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01566-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:58:38Z","timestamp":1613739518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01566-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,5]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01566-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,5]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study and DK were financed by the H2020 Marie Sklodowska-Curie Innovative Training Network 721236 grant. MN is co-financed by \u201cConsejer\u00eda de Educaci\u00f3n, Juventud y Deporte\u201d PEJ-2018-TL\/BMD-11080 grant from \u201cComunidad de Madrid\u201d and \u201cFondo Social Europeo\u201d. No Rapid Service Fee was received by the journal for the publication of this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"Wrote Manuscript: DK, MSR, PZ, SA, FAS; Designed Research: DK, FAS, MSR, GM, MR, DO; Performed Research: DK, MR, GM, FAS, MN; Analysed Data: DK, SA, ESM, EPS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship Contributions"}},{"value":"This was published previously as a preprint .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentation"}},{"value":"FAS and DO have been consultants or investigators in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, Cinfa, FAES, Farmal\u00edder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Silverpharma, Teva and Zambon. DK, MSR, PZ, SA, GM, MR, MN, ESM and EPS declare no conflict of interest. DK changed affiliation since the completion of the study to Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut, USA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The protocol was approved by its research ethics committee (Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica (CEIC) of Hospital de La Princesa, registry number 3411) authorized by the Spanish Drugs Agency and the study was performed under the guidelines of Good Clinical Practice and the Declaration of Helsinki. All subjects signed the informed consent before inclusion and were free to withdraw from the study at any time.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"All data generated or analysed during this study are included in this published article (and its supplementary material files). Clinical trial registry name, URL and registration number: TREATMENT-HV; EUDRA-CT 2018-000744-26; .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}